

A phase III, randomised, non-inferiority trial, to assess the efficacy and safety of dihydroartemisinin and piperazine (DHA + PPQ, Artekin®) in comparison with artesunate and mefloquine (AS + MQ) in patients affected by acute, uncomplicated Plasmodium falciparum malaria

Submission date 21/03/2005	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 05/05/2005	Overall study status Completed	☐ Protocol
Last Edited 25/07/2012	Condition category Infections and Infestations	☐ Statistical analysis plan
		☒ Results
		☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Nicholas J White

Contact details
Wellcome Trust Southeast Asian Tropical Medicine Research Units
Faculty of Tropical Medicine
Mahidol University
420/6 Rajvithi Road
Phayathai
Bangkok
Thailand
10400

Additional identifiers

Protocol serial number

ST3073+ST3074 DM040010

Study information

Scientific Title**Study objectives**

The primary objective of the study is to measure the Day 63, polymerase chain reaction (PCR) corrected cure rates of artekin and AS + MQ and demonstrate that:

1. The cure rate of Artekin is non-inferior to that of AS + MQ (non-inferiority margin = 5%)
2. The cure rate of Artekin is at least 90%

This cure rate is defined as the proportion of patients with adequate clinical and parasitological response at Day 63 plus those treatment failures identified as new infection by PCR.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Phase III, randomised, non-inferiority trial

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Malaria

Interventions

Randomisation will stratify infants, children and adults by age. Patients randomised to:

1. Tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine for adult patients or containing 20 mg of dihydroartemisinin and 160 mg of piperaquine for infants and children
2. Tablets containing 50 mg of artesunate and tablets containing 250 mg of mefloquine

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Dihydroartemisinin + Piperaquine (DHA + PPQ, Artekin®) in comparison with Artesunate + Mefloquine (AS + MQ)

Primary outcome(s)

The Day 63, PCR corrected cure rates of artekin and AS+MQ

Key secondary outcome(s)

1. The comparison of the uncorrected Day 63 cure rates of both drugs (also known as adequate clinical and parasitological response [ACPR])
2. The comparison of the amount of overall treatment failure
3. The comparison of the safety profiles of the two treatments
4. Proportion of patients with treatment failure (TF)
5. Proportion of aparasitaemic patients
6. Proportion of afebrile patients
7. Gametocytes carriage
8. Fractional change in haemoglobin/haematocrit

Completion date

01/01/2001

Eligibility**Key inclusion criteria**

1. Males and females aged between three months and 65 years inclusive
2. Body weight at least 5 kg
3. Microscopically confirmed, monoinfection of Plasmodium falciparum or mixed infection
4. History of fever or presence of fever (tympanic temperature at more than or equal to 37.5°C)
5. Written informed consent
6. 1050 patients (700 DHA + PPQ; 350 AS + MQ)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

All

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/2000

Date of final enrolment

01/01/2001

Locations

Countries of recruitment

India

Lao People's Democratic Republic

Thailand

Study participating centre

Wellcome Trust Southeast Asian Tropical Medicine Research Units

Bangkok

Thailand

10400

Sponsor information**Organisation**

Sigma-Tau (Italy)

ROR

<https://ror.org/03bxtpd68>

Funder(s)**Funder type**

Charity

Funder Name

Medicines for Malaria Venture (MMV) (Switzerland)

Alternative Name(s)

MMV

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

Switzerland

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	30/07/2010		Yes	No
Results article	results from India	20/07/2012		Yes	No